Get the Stockscreener App
2.68
5.96%
-0.17
After Hours:
1.76
-0.92
-34.33%
Biocardia Inc stock is traded at $2.68, with a volume of 201.00K.
It is down -5.96% in the last 24 hours and up +18.06% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$2.85
Open:
$2.82
24h Volume:
201.00K
Relative Volume:
2.66
Market Cap:
$9.22M
Revenue:
$468.00K
Net Income/Loss:
$-10.34M
P/E Ratio:
-0.3801
EPS:
-7.05
Net Cash Flow:
$-8.94M
1W Performance:
+36.04%
1M Performance:
+18.06%
6M Performance:
+12.13%
1Y Performance:
-52.36%
1-Day Range:
$2.55
$3.17
1-Week Range:
$2.23
$3.20
52-Week Range:
$1.625
$6.15
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.23 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 355.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.2199 | 318.40M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.50 | 211.65M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
4.00 | 156.75M | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - Yahoo
Form 8-KCurrent report - ADVFN
BioCardia Advances Cardiac Cell Therapy With Start Of Phase 3 CardiAMP HF II Trial - Nasdaq
BioCardia (BCDA) Moves Forward With Phase III CardiAMP HF II Tri - GuruFocus
BioCardia Enrolls First Patient in Phase III Trial - TipRanks
BioCardia's Revolutionary Cell Therapy Enters Final Testing Phase for Heart Failure TreatmentKey Trial Details - Stock Titan
BioCardia (BCDA) Gains Attention Amid Surge in Search Activity | - GuruFocus
Biocardia CFO David McClung buys $24,999 in company stock - Investing.com Australia
Biocardia CFO David McClung buys $24,999 in company stock By Investing.com - Investing.com UK
BioCardia Executives Increase Their Stakes in the Company - TradingView
Biocardia CEO Peter Altman acquires $1,488 in stock - MSN
Beating Heart Patch Market Detailed In New Research Report 2025 | - openPR.com
BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results - ADVFN
Biocardia CEO Peter Altman buys $214 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman buys $214 in company stock - Investing.com Australia
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Yahoo
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed By Investing.com - Investing.com South Africa
BioCardia (BCDA) Receives Positive DSMB Recommendation for Cardi - GuruFocus
Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial - marketscreener.com
BioCardia’s CardiALLO Trial Advances After Safety Review - TipRanks
BioCardia’s CardiALLO-HF trial receives DSMB nod to proceed - Investing.com
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic - GuruFocus
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - The Manila Times
Major Safety Milestone: Revolutionary Heart Failure Cell Therapy Advances to Next Phase - Stock Titan
Biocardia CEO Altman purchases shares worth $1,206 - Investing.com Australia
Biocardia CEO Altman purchases shares worth $1,206 By Investing.com - Investing.com India
Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Yahoo Finance
BioCardia (BCDA) Advances Phase III CardiAMP HF II Trial with Em - GuruFocus
BioCardia Initiates Patient Enrollment at Emory University Schoo - GuruFocus
Emory University joins phase III heart failure trial By Investing.com - Investing.com South Africa
BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial - marketscreener.com
Emory University joins phase III heart failure trial - Investing.com Australia
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - The Manila Times
Biocardia Initiates Patient Enrollment At Emory University School Of Medicine - MarketScreener
BioCardia CEO Peter Altman purchases $980 in company stock By Investing.com - Investing.com South Africa
BioCardia CEO Peter Altman purchases $980 in company stock - Investing.com
BioCardia completes enrollment for heart therapy trial - MSN
Biocardia CEO Peter Altman acquires $1,632 in company shares By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $1,632 in company shares - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock By Investing.com - Investing.com South Africa
Biocardia CEO Peter Altman acquires $2,688 in common stock By Investing.com - Investing.com Australia
Biocardia CEO Peter Altman buys $2,435 in company stock - Investing.com Australia
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):